Applied Therapeutics, Inc. financial data

Symbol
APLT on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Fifth Avenue, Suite 1400, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 142 % +38.2%
Debt-to-equity 240 % -92.2%
Return On Equity -578 % +89.6%
Return On Assets -170 % +2.12%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 115M shares +81.9%
Common Stock, Shares, Outstanding 115M shares +84.9%
Entity Public Float 63.9M USD +130%
Common Stock, Value, Issued 11K USD +83.3%
Weighted Average Number of Shares Outstanding, Basic 144M shares +82.1%
Weighted Average Number of Shares Outstanding, Diluted 152M shares +92.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 144K USD
Research and Development Expense 48.3M USD -8.9%
General and Administrative Expense 29.4M USD +22.5%
Operating Income (Loss) -78M USD -17.6%
Nonoperating Income (Expense) -83.1M USD -1107%
Net Income (Loss) Attributable to Parent -161M USD -120%
Earnings Per Share, Basic -1.52 USD/shares -70.8%
Earnings Per Share, Diluted -1.67 USD/shares -87.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 122M USD +243%
Cash, Cash Equivalents, and Short-term Investments 22.9M USD -58.9%
Other Assets, Current 598K USD +11.6%
Assets, Current 128M USD +198%
Operating Lease, Right-of-Use Asset 206K USD -67.2%
Assets 128M USD +193%
Accounts Payable, Current 2.68M USD -42.8%
Contract with Customer, Liability, Current 333K USD
Liabilities, Current 55.4M USD +17.3%
Operating Lease, Liability, Noncurrent 30K USD -82.4%
Liabilities 55.4M USD +15.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 51K USD
Retained Earnings (Accumulated Deficit) -550M USD -41.5%
Stockholders' Equity Attributable to Parent 72.4M USD
Liabilities and Equity 128M USD +193%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.9M USD -171%
Net Cash Provided by (Used in) Financing Activities 115M USD
Net Cash Provided by (Used in) Investing Activities 13.9M USD +45.6%
Common Stock, Shares Authorized 250M shares +25%
Common Stock, Shares, Issued 115M shares +84.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 96.6M USD +1443%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 122M USD +243%
Deferred Tax Assets, Valuation Allowance 151M USD +12.7%
Deferred Tax Assets, Gross 151M USD +12.6%
Operating Lease, Liability 215K USD -67.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -161M USD -120%
Lessee, Operating Lease, Liability, to be Paid 224K USD -67.2%
Operating Lease, Liability, Current 185K USD -61.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 23K USD -94.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 23K USD -94.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +35.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9K USD -66.7%
Deferred Tax Assets, Operating Loss Carryforwards 94.1M USD +6.84%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 622M USD +61.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 139K USD -48.9%
Share-based Payment Arrangement, Expense 7.73M USD -15.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%